BIO Reveals Program for 2013 BIO Convention in China
Washington, D.C. (October 31, 2013) – The Biotechnology Industry Organization (BIO) today announced panel sessions for the 3rd annual BIO Convention in China to be held November 11-13, 2013 in Beijing. The program will feature science-focused sessions such as vaccine development, China’s unmet medical needs and the research and development of orphan drugs to treat rare diseases in China, as well as business-focused sessions exploring China’s private health care industry, early-stage VC funding in China, and partnering models between Chinese and Western companies. Convention programming and exhibition will take place November 12-13.
“China has the potential to build a world-class innovative biologics sector," said Joseph Damond, senior vice president of international affairs at BIO. “This year’s BIO China program helps support that ambition by bringing together western and Chinese life sciences companies as well as business leaders, government officials and other industry representatives for learning and deal-making opportunities.”
Three can’t miss panels include:
· Company Partnerships in Vaccine Developments in China
China and its neighboring countries represent a significant private sector opportunity for new vaccines. Chinese vaccine companies, working in partnership with other vaccine companies, are developing important medicine that addresses the specific unmet medical needs in China and other Asian markets. These collaborations bring novel vaccine technology into the Chinese research institutions while offering small and large Western vaccine companies the opportunity to bring new products to the growing Chinese private sector. Vaccines that protect against pneumococcal disease, HPV, influenza and RSV are in development or clinical trials. The panelists for this topic will discuss successful partnerships designed to solve key public health issues in China and other emerging markets.
Tuesday, November 12, 11:00 a.m. – 11:55 a.m.
Moderator: Ralf Altmeyer, PhD, Director General, Institut Pasteur of Shanghai, Chinese Academy of Sciences
Panelists: Li Shi, CEO, Shanghai Zerun Biotech; Jean-Denis Shu, MD, Medical Director, Sanofi Pasteur, China
· Rare Diseases in China
The establishment of China’s first national organization against rare diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of orphan drugs in China.
Tuesday, November 12, 1:30 p.m. – 2:25 p.m.
Moderator: Kewen Jin, Managing Director, Nimbus Innoworks
Panelists: Rachel Lee, China Country President, Shire; Ko-Chung Lin, PhD, Founder & CEO, Pharmaessentia; Jerry Zeldis, PhD, Chief Executive Officer, Celgene Global Health and Chief Medical Officer, Celgene Corporation
· Dissecting China’s Unmet Medical Needs
The prevalence of cancer, diabetes and cardiovascular diseases continue to rise in China, primarily due to a growing aging population and urbanization. To what extent are current standards of care falling short, and what novel products and technologies are around the corner to fill the void? Hear leading experts discuss these questions, and learn how the industry is addressing unmet medical needs to improve healthcare in China.
Wednesday, November 13, 1:00 p.m. – 1:55 p.m.
Moderator: Nick Zhang, PhD, China General Manager, Senior Vice President, Frontage Lab
Panelists: Friedhelm Blobel, PhD, President & CEO, SciClone Pharmaceuticals; Bruno Osterwalder, MD, Senior VP, Senior Strategic Advisor Oncology, Global Drug Development and Medical, Merck Serono; Russell Wilson, Senior Vice President, Business Development, Novavax; Grace Xu, VP, Product Development & Strategic Planning, Bristol-Myers Squibb
Other BIO China sessions include:
· Roadmap to Cultivate Innovative Biologics Industry in China
The bio-industry has been designated as one of China’s seven strategic emerging industries (SEI) by the government. Within the bio-industry, therapeutic biologics hold significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in many disease areas. Today, China’s therapeutic biologics industry stands at RMB 18 billion, representing less than 2 percent of the global total. This panel will explore the steps that may be taken by the government and industry to develop a world-class innovative biologics sector in China.
· State of Capital Markets in US
With capital markets opening up, 2013 saw 39 (and counting) new biotech IPOs – many of which are staying strong even after their initial debut. Will this excitement continue onto 2014 and translate into new opportunities for China? This panel will explore the state of the capital markets in China in comparison to the exciting new developments in the U.S. through the prism of biotech insiders, as well as assess the current and future attractiveness of local IPOs, providing a global and insightful perspective to both companies and investors.
· China’s Private Health Care Industry
China has committed to making private healthcare a larger part of the overall ecosystem, aiming for 20% of beds and 20% of spending to be conducted through private institutions by 2020. This panel will explore the opportunities and challenges for private insurers, providers, pharmaceutical companies and device manufacturers looking to capitalize on the rapidly growth in private healthcare.
· Early-stage VC funding in China
While there are still only a few early-stage bio-investors in China, the number of funding sources is starting to increase, kick-starting Chinese biotech. Where will this diversity of investments take China’s biotech industry in the coming years? Hear investors assess the current state of early-stage VC funding in China and the long-term outlook for biotech.
· Case Studies: Partnering Models between Chinese & Western Companies
Through in-licensing, out-licensing, JV/Alliances and M&A, an increasing number of Chinese and Western companies are collaborating to bring therapeutics to the market. This session will highlight recent deals from 2013 to discuss their respective deal structures, what companies need to consider to produce the most fruitful partnerships, and where they see China and Western collaborations moving in the future.
In addition to panel sessions, BIO China will host company presentations, partnering meetings and networking opportunities. Keynote speakers will include:
· Governor Jay Inslee, Washington State
· Gary F. Locke, Ambassador of the United States of America to the People’s Republic of China
· Bian Zhenjia, Assistant Minister, CFDA
· Zhao Yajun, Director General, China Center for Pharmaceutical Exchange
· James C. Greenwood, President and CEO, Biotechnology Industry Organization
BIO brings to China more than 17 years of experience in organizing international conferences for the biotech industry, including the BIO International Convention, the world’s largest annual biotech conference. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering™, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors.
For more information on the BIO Convention in China, please visit here.
Upcoming BIO Events
BIO IPCC Conference
November 6-8, 2013
Washington, DC
BIO Convention in China
November 11-13, 2013
Beijing, China
Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 8-11, 2013
San Diego, CA
BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY
BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan
World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA
BIO International Convention
June 23-26, 2014
San Diego, CA
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, South Dakota